Tugce Kubra Gunes Capar

Dr. Tugce Kubra Gunes Capar

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 August 2025 in Therapeutic Advances in Medical Oncology
Verified
Journal Article
Open access
OKOgur Karhan
Ogur Karhan
SISerdar İlEri
Serdar İlEri
ZUZuhat Urakçı
Zuhat Urakçı
YSYasin Sezgin
Yasin Sezgin
ÜYÜmit Yıldırım
Ümit Yıldırım
STSezai TUNÇ
Sezai TUNÇ
Background: Metastatic gastric cancer (GC) and gastroesophageal junction (GEJ) cancer are associated with a poor prognosis. Recent advancements in treatment have incorporated trastuzumab, anti-PD-1 agents, and anti-claudin therapies alongside chemotherapy (ChT), significantly improving outcomes. Contemporary studies predominantly employ doublet ChT as the backbone for these regimens, although historically triplet ChT regimens have been favored, particularly in younger patients requiring rapid tumor shrinkage. Objective: The aim of this study was to compare the efficacy of mFOLFOX-6 and mDCF regimens in the treatment of advanced GC and GEJ adenocarcinoma. Design: This was a retrospective multicenter study. Methods: Patient data were obtained from the databases of 25 hospitals across Turkey. Demographic and clinicopathological characteristics were documented. Overall survival (OS) and progression-free survival (PFS) were analyzed using the Kaplan–Meier method, and group discrepancies were assessed with log-rank test. Results: A total of 493 patients were included in the analysis, with similar baseline characteristics between the two groups. The objective response rate was 36.3% in the mDCF group and 38% in the mFOLFOX-6 group ( p = 0.7). The median PFS was 6 months for mDCF and 7 months for mFOLFOX-6 ( p = 0.2), while the median OS was 12 months for mDCF and 11 months for mFOLFOX-6 ( p = 0.4). Grade 3–4 neutropenia occurred in 27.6% of patients treated with mDCF versus 17.8% with mFOLFOX-6 ( p = 0.01). Likewise, grade 3–4 anemia was more frequent in the mDCF group (9.5%) compared to the mFOLFOX-6 group (4.8%; p = 0.04). Conclusion: Modified FOLFOX-6 demonstrated comparable efficacy to mDCF in the treatment of advanced GC and GEJ adenocarcinoma. Moreover, mFOLFOX-6 was associated with a lower incidence of hematological adverse effects.

1 July 2026 in Current Cancer Drug Targets
Verified
Journal Article
Closed access
ABAyberk Bayramgil
Ayberk Bayramgil
TCTugce Kubra Gunes Capar
Tugce Kubra Gunes Capar
FAFatma Gulcicek Ayranci
Fatma Gulcicek Ayranci
DADuygu Yoruk Atik
Duygu Yoruk Atik
BNBusra Nigdelioglu
Busra Nigdelioglu
OKOzgecan Dulgar Kaya
Ozgecan Dulgar Kaya
Introduction/Background: Cholangiocarcinoma (CC) is a rare, aggressive cancer of the bile ducts with limited treatment advancements over recent decades. The five-year survival rate for CC remains low, around 10%, and even lower for advanced cases. Case Presentation: This case report discusses a 46-year-old woman with metastatic CC who achieved remarkable progression-free survival with regorafenib, a multikinase inhibitor typi-cally used in other cancers. After multiple lines of treatment, regorafenib was given as a 7th-line therapy. Despite initial intolerance requiring dose reduction, the patient achieved 22 months of progression-free survival (PFS) with stable disease and partial regression in some areas. Her response to regorafenib significantly exceeded typical outcomes in the literature, where PFS generally ranges from 3 to 4 months. This improvement may be attributed to an FGFR2 mutation identified via next-generation sequencing, which regorafenib may effec-tively target. Conclusion: This case suggests that patients with FGFR2 mutations might benefit from regorafenib, warranting further studies to explore this associationAs can be applied as a promising target gene to develop drug resistance and remedial efficacy.

19 September 2025 in International Journal of Cancer
Verified
Journal Article
Closed access
GŞGökhan Şahin
Gökhan Şahin
ETEsmanur Kaplan Tüzün
Esmanur Kaplan Tüzün
HGHalil Göksel Güzel
Halil Göksel Güzel
MGMurad Guliyev
Murad Guliyev
ADAhmet Kürşad Dişli
Ahmet Kürşad Dişli
HYHasan Çağrı Yıldırım
Hasan Çağrı Yıldırım

20 August 2025 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
AKAli Kalem
Ali Kalem
TKTülay Kuş
Tülay Kuş
SGSavas Gokcek
Savas Gokcek
IUIlkay tugba Unek
Ilkay tugba Unek
TSTaha Koray Sahin
Taha Koray Sahin
SYSuayib Yalcin
Suayib Yalcin
Background: Adenocarcinoma arising from the ampulla of Vater is an extremely rare neoplasm, and there are limited data regarding frontline therapy for metastatic disease. We investigated the outcomes of first-line treatment with FOLFIRINOX by comparing it with other treatments in patients with advanced ampullary adenocarcinoma. Methods: We included 123 patients with advanced ampullary adenocarcinoma who were treated with frontline FOLFIRINOX (n = 32), fluorouracil (FU)-based chemotherapy (n = 20), and gemcitabine-based chemotherapy (n = 65) between August 2007 and January 2024 in this retrospective study. The median progression-free survival (mPFS) and overall survival (mOS) according to treatment and clinicopathological features were calculated using the Kaplan–Meier method. Results: The median age of the patients was 62 years (range, 36–78), and 75,6% of the patients had an ECOG performance status of 0–1. The mOS were 13 months (95% CI, 10.6–14.4), 11 months (95% CI, 10.6–14.4), and 12 months (95% CI, 10.6–14.4), respectively [p = 0.865]. There were no significant differences in OS among the chemotherapeutic agents according to histological subtypes. However, FOLFIRINOX and FU-based treatments appeared more effective in the intestinal subtype, while gemcitabine-based therapies were less effective. In the pancreaticobiliary subtype, FU-based therapies yielded a shorter outcome compared to FOLFIRINOX and gemcitabine-based therapies. Grade 3 or 4 hematologic toxicities were higher in patients treated with FOLFIRINOX. Conclusions: In advanced ampullary adenocarcinoma, despite higher toxicity, frontline FOLFIRINOX showed a trend toward an OS benefit in the intestinal subtype while providing a similar outcome in the pancreaticobiliary subtype.

22 August 2025 in Cancers
Verified
Journal Article
Open access
PDF file
AKAli Kalem
Ali Kalem
TKTulay Kus
Tulay Kus
TSTaha Koray Sahin
Taha Koray Sahin
ÖDÖmer Dizdar
Ömer Dizdar
SESafa Can Efil
Safa Can Efil
SYSuayib Yalcin
Suayib Yalcin
Background: Ampullary adenocarcinoma is a rare cancer for which there are no standard adjuvant treatment recommendations due to the lack of randomized clinical trials. The primary aim of this analysis is to investigate the efficacy of adjuvant FOLFIRINOX treatment in patients with resected ampullary adenocarcinoma. Materials and Methods: This multicenter retrospective cohort study was conducted at 15 institutions in Turkey between August 2007 and January 2024, involving 211 patients with resected, non-metastatic ampullary adenocarcinoma receiving adjuvant chemotherapy with various chemotherapy regimens with or without chemoradiation. Clinicopathological and treatment-related parameters were recorded. Disease-free survival (DFS) and overall survival (OS) were analyzed by using Kaplan–Meier estimates. Cox proportional hazards regression was used to identify covariates associated with OS. Results: The median follow-up time was 52 months, and 116 patients (55.2%) were alive at the time of the analysis. The median age was 61 years (32–82). mFOLFIRINOX was administered to 16.6% of the patients (n = 35). The 3-year DFS rate was 79.41% in the FOLFIRINOX-treated arm and 53.9% in the other treatment arm (p = 0.034 for mDFS). The median OS was non-reached in patients receiving mFOLFIRINOX treatment, while it was 51 months in patients receiving other treatments (p = 0.071). While no statistically significant results were reached, a trend toward statistically significant survival times was observed in the FOLFIRINOX arm. After adjustment for other prognostic parameters, mFOLFIRINOX remained an independent statistically significant parameter for better OS (HR; 95% CI: 3.24; 1.02–10.9; p = 0.046). Conclusions: FOLFIRINOX treatment has shown efficacy in the adjuvant treatment of ampullary cancer, independent of histological subtype. The findings should be validated in large prospective trials.

16 August 2026 in Diagnostics
Verified
Journal Article
Open access
PDF file
TCTugce Kubra Gunes Capar
Tugce Kubra Gunes Capar
PÖPirilti Özcan
Pirilti Özcan
MSMuzeyyen Muge Savas
Muzeyyen Muge Savas
ÖDÖzgül Düzgün
Özgül Düzgün
MÖMelike Özçelik
Melike Özçelik
Background: Accurate staging in gastric cancer is essential for optimal treatment planning. Diagnostic laparoscopy (DL) plays a crucial role in detecting occult peritoneal metastases not identified by conventional imaging. This study aimed to evaluate the impact of DL on clinical decision-making and treatment allocation in patients with gastric cancer. Methods: We retrospectively analyzed consecutive patients treated between June 2016 and March 2026 at a tertiary Surgical Oncology Center. All patients underwent diagnostic laparoscopy with peritoneal lavage and biopsies. Patients were stratified according to the Peritoneal Cancer Index (PCI) and directed to appropriate treatment pathways, including CRS + HIPEC, PIPAC combined with systemic chemotherapy, or neoadjuvant chemotherapy followed by surgical re-evaluation. Results: Occult peritoneal metastases were detected in 20% of patients (80/400). Among patients with peritoneal metastasis, 70 patients ultimately underwent CRS + HIPEC and 39 underwent PIPAC-based treatment. Among these 70 patients, 53 patients with PCI < 7 were initially allocated to CRS + HIPEC and an additional 17 patients with newly detected limited peritoneal disease (PCI < 7) underwent CRS + HIPEC following restaging laparoscopy after neoadjuvant chemotherapy, resulting in a total of 70 patients in the CRS + HIPEC group. In the CRS + HIPEC group, the 1-year survival rate was 70% with a morbidity rate of 25.7%. In the PIPAC group, the 1-year survival rate was 50% with a morbidity rate of 25.6%. Among patients receiving neoadjuvant chemotherapy, disease progression was detected in 14% during restaging laparoscopy. Palliative surgery provided effective symptom control in inoperable patients, with a 1-year survival rate of approximately 15%. Conclusions: Diagnostic laparoscopy provides additional staging information and guides treatment allocation in patients with advanced gastric cancer. PCI-based assessment enables individualized selection of CRS + HIPEC, PIPAC, or systemic treatment strategies. However, the present study was not designed to determine whether DL-guided treatment allocation improves survival, and the observed survival outcomes should therefore be interpreted as descriptive real-world outcomes rather than evidence of treatment benefit.